Gainers

• Profusa (NASDAQ:PFSA) stock rose 48.6% to $0.86 during Thursday's regular session.
• Cocrystal Pharma (NASDAQ:COCP) shares rose 45.1% to $1.48. The market value of their outstanding shares is at $14.0 million. As per the news, the Q4 earnings report came out 2 days ago.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock increased by 35.32% to $0.12.
• Axe Compute (NASDAQ:AGPU) shares rose 20.78% to $4.3. The market value of their outstanding shares is at $12.0 million. As per the press release, Q4 earnings came out 2 days ago.
• Relay Therapeutics (NASDAQ:RLAY) shares rose 19.68% to $12.89. The market value of their outstanding shares is at $1.8 billion.
• Lexaria Bioscience (NASDAQ:LEXX) stock rose 18.92% to $1.03. The company's market cap stands at $21.5 million.

Losers

• Lipocine (NASDAQ:LPCN) shares decreased by 78.4% to $2.0 during Thursday's regular session. The market value of their outstanding shares is at $67.5 million.
• Inovio Pharmaceuticals (NASDAQ:INO) stock fell 36.9% to $1.1. The market value of their outstanding shares is at $120.2 million.
• IO Biotech (NASDAQ:IOBT) shares declined by 26.09% to $0.03. The company's market cap stands at $3.1 million.
• Bullfrog AI Hldgs (NASDAQ:BFRG) stock declined by 24.08% to $1.23. The company's market cap stands at $20.5 million.
• Onconetix (NASDAQ:ONCO) stock decreased by 21.08% to $1.48. The market value of their outstanding shares is at $1.2 million.
• CDT Equity (NASDAQ:CDT) shares fell 18.63% to $4.15. The market value of their outstanding shares is at $24.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.